Investor Login

Horizon Quantum Computing Raises USD 18.1 million Series A to Advance Quantum Software Development

Horizon Quantum Computing Raises USD 18.1 million Series A to Advance Quantum Software Development

SINGAPORE--March 31, 2023--Horizon Quantum Computing, a Singapore-based company building software development tools to unlock the potential of quantum computing hardware, announced today that it has raised USD 18.1 million Series A investment from Sequoia Capital India, Tencent, SGInnovate, Pappas Capital and Expeditions Fund.

The investment round will boost the growth of the company, allowing it to strengthen its science and engineering teams to accelerate product development, establish its new engineering centre in Europe and bring Horizon’s unique technology to the market. Horizon Quantum Computing’s total funding now stands at approximately USD 21.3 million.

0-Homepage Feature / 0-Megaphone / Horizon - 03/31/2023

Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older

FOSTER CITY, Calif.-- March 14, 2023 -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a reduction in age from one year to three months for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The label expansion was based on data from the RISE study which characterized the safety and tolerability of LIVMARLI in infants under one year of age with ALGS.

Mirum Pharmaceuticals - 03/15/2023

Us2.ai to Deliver AI-Enabled Echocardiography Decision Support to Brigham and Women’s Hospital’s Cardiac Imaging Core Laboratory

SINGAPORE--(BUSINESS WIRE)--Us2.ai, a Singapore-based medtech firm backed by IHH Healthcare, Heal Partners and Sequoia India will provide AI software that assists in analyzing research echocardiograms or heart ultrasounds to Brigham and Women’s Hospital’s Cardiac Imaging Core Laboratory. Us2.ai’s software platform aims to improve the speed and scalability of the Cardiovascular Imaging Core Laboratory (CICL), part of the Brigham and Women’s Hospital (BWH) Division of Cardiovascular Medicine.

Us2.ai - 02/23/2023

SG energy storage firm VFlowTech raises $10m in Series A funding

SINGAPORE, 7 February 2023 – VFlowTech, the Singapore-based provider of vanadium-based redox flow batteries, has raised US$10 million in a Series A funding round. Led by Japan-based venture capital (VC) firm Real Tech Holdings, the oversubscribed round was participated in by returning investors ranging from corporate investors including SEEDS Capital, Wavemaker Partners and Sing Fuels to personal investors like Michael Gryseels (Chairman of VFlowTech), as well as new international VC and strategic investors including İnci Holding (Türkiye), Pappas Capital (US) and Carbon Zero Venture Capital (Singapore). VFlowTech will use the funds to set-up a 200MWh production line capacity and scale up the manufacturing of its 250 kWh modular vanadium-based long duration energy storage solutions. It will also use the funds to expand its market presence to Türkiye, the US, Japan, China and India with new partners. The company also plans to intensify research and development efforts to further improve its best-in-class technology, as well as increase system capacity and explore new markets with emerging demand for sustainable energy storage solutions.

VFlowTech - 02/07/2023

Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)

FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial intrahepatic cholestasis (PFIC) in a broad range of subtypes, age one to 17 years. The primary endpoint of improvement in pruritus severity in PFIC2 was statistically significant (p=0.0098).

“The advancement of new medications, particularly for rare diseases like PFIC, is incredibly important and provides hope to families who are in need of a treatment option that can effectively address itch, the most burdensome aspect of the disease”

The primary analysis was conducted in PFIC2 patients (n=31). The secondary analyses were evaluated in the All-PFIC cohort, which included PFIC2 as well as additional PFIC subtypes (n=64). The Full-Study population included All-PFIC as well as supplemental patients who had previously undergone surgery, had truncating mutations and other patients (n=93).

Mirum Pharmaceuticals - 10/24/2022

Aidoc expands cardiology solutions by bringing Us2.ai's echo AI into proprietary operating system

NEW YORK, Oct. 20, 2022 -- Aidoc, the leading provider of healthcare AI solutions, announced today a partnership with Us2.ai to bring its FDA-cleared and CE Marked AI algorithm to analyze and interpret echocardiograms (echo) into its proprietary aiOS™.

Within Aidoc's aiOS – a first-in-market operating system that can orchestrate multiple independent AI algorithms across the native workflows of various specialties – the Us2.ai algorithm can deliver a fully automated and standardized echo report to sonographers and cardiologists.

Us2.ai - 10/22/2022

Recipients of the 2022 WIA Demeter Award of Excellence Announced

Topsfield, Mass., (August 25, 2022) – Three exceptional women have been named recipients of the 2022 Women in Agribusiness (WIA) Demeter Award of Excellence – Diane Allemang of FMC Corporation, Kendall Jones of ProAg and Karen LeVert of Pappas Capital and Ag TechInventures. The trio will be recognized next month at the 11th annual Women in Agribusiness Summit, which will be held in Dallas, September 26-28, at the Hyatt Regency Dallas.

Karen LeVert - 09/01/2022

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million. The extension included participation from new premier healthcare investors Cowen Healthcare Investments, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., ArrowMark Partners, Mirae Asset Venture Investment, Timefolio Capital (formerly known as NS Investment), Pappas Capital, and other undisclosed participants. All existing investors MPM Capital, Vida Ventures, EcoR1 Capital, Octagon Capital, TCG Crossover, Bristol Myers Squibb, and Novartis participated in the financing.

Aktis Oncology / Specialized Holdings - 08/25/2022
logo_white
veteran_logo_white
NVCA
bio
nc-biotech